About this trial
This study is a single-center, observational study designed to collect tissue spectrometric data.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults, age of 18 - 90 years
Scheduled for plastic surgical reconstructive flap operation
Ability and willingness to provide informed consent.
Disqualifiers
Unable to provide signed informed consent
Considered a vulnerable person according to the Finnish Medical Research Act (488/1999), Chapter 2, Sections 7, 9, and 10, including retarded persons, pregnant women, nursing mothers, prisoners, and forensic patients.
Trial population
Patients scheduled for plastic surgical reconstructive flap operation in the Helsinki University Central Hospital.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Observe changes in flap tissue oxygenation
To observe the changes in flap tissue oxygenation (combined hemoglobin/myoglobin saturation, %) measured by the SpectroCor Monitoring System during the ischemia-reperfusion sequence of microvascular flap reconstruction. Continuous spectroscopic measurement of combined hemoglobin and myoglobin oxygen saturation in the transferred flap tissue, recorded from a SpectroCor Sensor inserted into the flap, with a second sensor placed in subcutaneous tissue of the distal wound. Saturation values are time-stamped against intraoperative events affecting flap perfusion (pedicle division and flap detachment from the donor site, completion of the microvascular anastomosis, release of the vascular clamp and reperfusion, and any anastomotic revision) and compared with paired arterial and venous blood gas samples obtained at the beginning and at the end of the surgery.
Secondary outcomes
Incidence of adverse events, adverse device effects, and device deficiencies
Number and proportion of participants experiencing at least one adverse event (AE), adverse device effect (ADE), serious adverse event (SAE), serious adverse device effect (SADE), or unanticipated serious adverse device effect (USADE), and the number of device deficiencies (DD) recorded. Events are recorded from the time of sensor placement until discharge from hospital and assessed for causal relationship to the investigational device by the investigator. Anticipated device-related events include topical bleeding at the sensor attachment site, local tissue reaction associated with tissue glue fixation, and local infection at the insertion site.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Spectrocor
Lead sponsor
Helsinki University Central Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options: